Abstract
Objectives The COVID-19 pandemic has affected cancer care worldwide. This study aimed to estimate the long-term impacts of the pandemic on cancer incidence and mortality in Canada using a mathematical model.
Methods We developed a stochastic microsimulation model to estimate the cancer care disruptions and its long-term impact on cancer incidence and mortality in Canada. The model reproduces cancer incidence, survival, and epidemiology in Canada, by using cancer incidence, stage at diagnosis and survival data from the Canadian Cancer Registries. We modeled reported declines in cancer diagnoses and treatments recorded in provincial administrative datasets from March 2020-June 2021. We assumed that diagnostic and treatment delays lead to an increased rate of death. Based on the literature, we assumed each 4-week delay in diagnosis and treatment would lead to a 6% to 50% higher rate of cancer death. Results are the median predictions of 10 stochastic simulations.
Findings The model predicts that cancer care disruptions during the COVID-19 pandemic could lead to 21,247 (2·0%) more cancer deaths in Canada in 2020-2030, assuming treatment capacity is recovered to 2019 pre-pandemic levels in 2021. This represents 355,172 life years lost expected due to pandemic-related diagnostic and treatment delays. The highest absolute expected excess cancer mortality was predicted in breast, lung, and colorectal cancers, and in the provinces of Ontario, Québec, and British Columbia. Diagnostic and treatment capacity in 2021 onwards highly influenced the number of predicted cancer deaths over the next decade.
Interpretation Cancer care disruptions during the Covid-19 pandemic could lead to significant life loss; however, most of these could be mitigated by increasing diagnostic and treatment capacity in the post-pandemic era to address the service backlog.
Funding Canadian Institutes of Health Research
Evidence before this study We performed a review of modeling studies predicting the impact of pandemic-induced disruptions to cancer care on cancer survival outcomes. We searched MEDLINE on 2 July 2021 for records published from 1 January 2020 with no language restrictions. Our search consisted of index keywords [Cancer AND COVID-19 AND [(delay AND diagnosis) OR (delay AND screening) OR (delay AND treatment)] AND outcomes AND modelling study]. We identified 14 studies that model the long-term effect of disruptions to cancer screening programs, diagnostic intervals, and to treatment intervals for common cancers. Most studies (9/14) assessed the impact of cancer screening disruptions but did not assume any treatment disruptions. Disruptions to cancer screening services in high income health systems were estimated to lead to small increases in cancer incidence and mortality, even with immediate resumption of screening to services after disruption periods. Fewer studies examined the impact of diagnostic referral and treatment disruptions; these are similarly predicted to lead to increases in cancer incidence and mortality, with varying impacts depending on cancer site. Due to difficulties in obtaining real-time healthcare data, previous studies have relied on assumptions regarding the duration of health care disruptions (1-, 3-, 6-, 12-, to 24-months) rather than on empirical data. All studies restricted their analysis to the impact on a single or a few cancer sites.
Added value of this study Our stochastic microsimulation model is the first to assess the population-level impact of diagnostic and treatment disruptions on overall cancer mortality across all sites. Using Canadian cancer statistics and expert validation of treatment modalities, we constructed a model that reproduced pre-pandemic cancer mortality data. An important added value of this analysis compared to previous studies was that we were able to integrate empirical data on cancer-related procedures during the pandemic era to model disruptions to cancer care.
Implications of all the available evidence We estimate there could be a 2·0% increase over expected cancer mortality between 2020-2030 in Canada due to pandemic-related disruptions to diagnostic and treatment intervals. Our results identified that a 10-20% increase in cancer care service capacity over pre-pandemic levels could prevent a considerable amount of the predicted excess cancer-related deaths by reducing diagnostic and treatment backlogs. By stratifying our reported outcomes by sex, age, province, and cancer site, we provide a long-term perspective that can inform post-pandemic public health policy or aid in prioritization of patients in the event of a resurgence of COVID-19. While our model is specific to Canada, it could be applied to countries that have experienced comparable COVID-19-related healthcare disruptions.
Competing Interest Statement
TM, JY, and PT have no conflicts of interest to disclose. ELF reports grants to his institution from CIHR during the conduct of the study; personal fees from Merck; a patent related to the discovery “DNA methylation markers for early detection of cervical cancer”, registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada. WM reports grants to his institution from Merck, CIHR, Cancer Research Society, Terry Fox Research Institute, Samuel Waxman Cancer Research Foundation, and CCSRI; consulting fees from Merck, BMS, Roche, GSK, Novartis, Amgen, Mylan, EMD Serono; honoraria from McGill university, Jewish General Hospital, BMS, Merck, Roche, GSK, Novartis, Amgen, Mylan, EMD Serono; payments for participation on an advisory board from BMS, Merck, Roche, Novartis, Amgen, GSK; and payments to his institution from BMS, Novartis, GSK, Roche, AstraZeneca, Methylgene, MedImmune, Bayer, Amgen, Merck, Incyte, Pfizer, Astellas, Genetech, Ocellaris Pharma, MIMIC, Exelixis, Roche, Alkermes in the past 36 months.
Funding Statement
This work was supported by the Canadian Institutes of Health Research [operating grant VR5-172666 and foundation grant 143347 to ELF]. The model simulations were run using the supercomputer Béluga from école de technologie supérieure, managed by Calcul Québec (www.calculquebec.ca/) and Compute Canada (www.computecanada.ca). The operation of this supercomputer is funded by the Canada Foundation for Innovation (CFI), Ministère de l’économie, des Sciences et de l’Innovation du Québec (MESI) and the Fonds de recherche du Québec - Nature et technologies (FRQ-NT). The companion web application was developed with in-kind support from the Canadian Partnership Against Cancer. The funders played no role in the writing of the manuscript, the collection/analysis of the data, or the decision to submit it for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is based on the analysis of public population-based data and does not require ethical approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵(Core Group) Wilson Miller, Eduardo Franco, Rami Ali, Mariam El-Zein, Eliya Farah, Farzin Khosrow-Khavar, Caroline Lambert, Talia Malagón, Luca Petruccelli, Gayle Shinder; (Members Serving an Advisory Role) Armen Aprikian, Jamil Asselah, Sarit Assouline, Hitesh Bhanabhai, Gerald Batist, Christine Bouchard, Matthew Cheng, Fabio Cury, Sinziana Dumitra, Arielle Elkrief, Melissa Henry, Carmen Loiselle, Antoine Loutfi, Christine Maheu, Ari Meguerditchian, Sarkis Meterissian, Michael Pollak, Shannon Salvador, Donald Sheppard, Erin Strumpf, Stephanie Wong; (Expert Oncology Practice Advisory Group): Joanne Alfieri, Armen Aprikian, Boris Bahoric, Gerald Batist, Marylise Boutros, Chantal Cassis, Fabio Cury, Marc David, Sinziana Dumitra, Lorenzo Ferri, Carolyn Freeman, Michael Hier, Tarek Hijal, Sender Liberman, Victor McPherson, Ari Meguerditchian, Sarkis Meterissian, Wilson Miller, Victoria Mandilaras, Alex Mlynarek, Thierry Muanza, Michael Palumbo, Valerie Panet-Raymond, Kevin Petrecca, Gizelle Propadi, Shannon Salvador, Sonia Skamene, Khalil Sultanem, Robert Turcotte, Te Vuong, Stephanie Wong.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.